KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Novartis Ag (NVS) Accumulated Expenses (2017 - 2025)

Novartis Ag's Accumulated Expenses history spans 9 years, with the latest figure at $1.0 billion for Q4 2025.

  • For Q4 2025, Accumulated Expenses rose 15.98% year-over-year to $1.0 billion; the TTM value through Dec 2025 reached $1.0 billion, up 15.98%, while the annual FY2025 figure was $1.0 billion, 15.98% up from the prior year.
  • Accumulated Expenses for Q4 2025 was $1.0 billion at Novartis Ag, up from $901.0 million in the prior quarter.
  • Across five years, Accumulated Expenses topped out at $1.1 billion in Q4 2022 and bottomed at $116.0 million in Q4 2023.
  • The 5-year median for Accumulated Expenses is $901.0 million (2024), against an average of $649.6 million.
  • The largest annual shift saw Accumulated Expenses crashed 89.12% in 2021 before it soared 733.86% in 2022.
  • A 5-year view of Accumulated Expenses shows it stood at $127.0 million in 2021, then surged by 733.86% to $1.1 billion in 2022, then tumbled by 89.05% to $116.0 million in 2023, then surged by 676.72% to $901.0 million in 2024, then rose by 15.98% to $1.0 billion in 2025.
  • Per Business Quant, the three most recent readings for NVS's Accumulated Expenses are $1.0 billion (Q4 2025), $901.0 million (Q4 2024), and $116.0 million (Q4 2023).